Company Encyclopedia
View More
name
Fidelity MSCI Health Care Index
FHLC.US
News
View More

MFG Wealth Management Inc. Acquires Shares of 6,431 AbbVie Inc. $ABBV

MFG Wealth Management Inc. acquired 6,431 shares of AbbVie Inc. (NYSE:ABBV) in the third quarter, valued at approximately $1,489,000. AbbVie reported Q3 earnings of $1.86 per share, beating estimates, with revenue of $15.78 billion. The company increased its quarterly dividend to $1.73 per share. Analysts have given AbbVie a consensus rating of 'Moderate Buy' with an average target price of $245.84.

Market Beat·
US
ABBV
+1.80%
Market Beat·
US
ABBV
+1.80%

Ipswich Investment Management Co. Inc. Has $5.34 Million Stock Holdings in Eli Lilly and Company $LLY

Ipswich Investment Management Co. Inc. increased its stake in Eli Lilly and Company by 21.3% in the third quarter, owning 6,995 shares valued at $5.34 million. This makes Eli Lilly 1.2% of Ipswich's holdings. Other institutional investors, like Vanguard and Norges Bank, also adjusted their stakes. Eli Lilly's stock has a consensus 'Moderate Buy' rating with an average target price of $1,141.73. The company reported strong quarterly earnings, with revenue up 53.9% year-over-year.

Market Beat·
US
LLY
+1.38%
Market Beat·
US
LLY
+1.38%

Dynamic Advisor Solutions LLC Purchases 4,692 Shares of Eli Lilly and Company $LLY

Dynamic Advisor Solutions LLC increased its stake in Eli Lilly by 54.8% in Q3, owning 13,261 shares worth $10.1 million. Other firms also adjusted their positions. Analysts have issued positive ratings, with a consensus of 'Moderate Buy' and a price target of $1,141.73. Eli Lilly's oral GLP-1 pill orforglipron showed positive trial results, boosting prospects for FDA approval and commercial adoption.

Market Beat·
US
LLY
+1.38%
Market Beat·
US
LLY
+1.38%

Bartlett & CO. Wealth Management LLC Raises Holdings in UnitedHealth Group Incorporated $UNH

Bartlett & CO. Wealth Management LLC increased its holdings in UnitedHealth Group by 7.2% in Q3, now owning 182,792 shares valued at $63,119,000. Other investors also adjusted their positions. Analysts have given mixed ratings, with a consensus "Hold" and an average target price of $385.54. UnitedHealth is focusing on transparency and operational changes, with analysts viewing it as a potential long-term buy despite near-term volatility.

Market Beat·
US
UNH
-0.22%
Market Beat·
US
UNH
-0.22%

Rep. Thomas H. Kean, Jr. Sells Shares of Johnson & Johnson (NYSE:JNJ)

Rep. Thomas H. Kean, Jr. (R-New Jersey) sold between $15,001 and $50,000 in Johnson & Johnson stock on November 20th, as disclosed in a December 19th filing. The transaction was made through his "STATE STREET BANK & TRUST CO." account. Additionally, he made other trades, including buying shares of Texas Instruments and selling shares of Stryker and Fiserv. Johnson & Johnson's stock performance and recent FDA approvals are also highlighted, with analysts maintaining a positive outlook on the company's growth and valuation.

Market Beat·
US
JNJ
-0.93%
Market Beat·
US
JNJ
-0.93%
© 2025 Longbridge｜Disclaimer